The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Financial details were not disclosed.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

pharmaphorum

SEPTEMBER 18, 2020

All eyes may be on Moderna’s COVID-19 vaccine at the moment, but the US biotech hasn’t been idle in business development elsewhere, signing back-to-back deals with Vertex and Chiesi that have brought in $100 million upfront. .

Gene Editing 105

Gene Editing Gene Vaccination Vaccine 105

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells).

Sales 91

Sales Manufacturing FDA Approval Life Science 91